Shares in Irish medical technology firm Trinity Biotech slumped by over 50pc yesterday, slashing $150m from its market capitalisation in New York, after the US Food and Drug Administration (FDA) asked the company to withdraw an application for approval for a product aimed at detecting heart attacks.